News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mallinckrodt Pharmaceuticals (MNK) And Questcor Pharmaceuticals, Inc. (Headquarters) (QCOR) Announce Early Termination Of HSR Act Waiting Period


5/12/2014 9:01:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Ireland & ANAHEIM, Calif.--(BUSINESS WIRE)--Mallinckrodt plc (NYSE: MNK), and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Mallinckrodt’s proposed acquisition of Questcor, was terminated by the United States Federal Trade Commission on May 9, 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES